Please provide your email address to receive an email when new articles are posted on . In the STEP trials, a higher proportion of adults receiving semaglutide stopped antihypertensive or ...
Sanofi and Regeneron’s PCSK9 inhibitor alirocumab—one of a group of antibodies heralded as the next class of cholesterol-lowering agents—has had its day in the Barcelona sun at the European Society of ...
PHILADELPHIA -- A novel anti-PCSK9 monoclonal antibody with a distinctive longer duration of action reduced cholesterol and other lipids in the phase III REMAIN-2 trial. Recaticimab showed long-term ...
A new survey suggests that most Americans are familiar with statins, but most are not aware of nonstatin cholesterol-lowering therapies and other tools to combat heart disease.The survey of 1,006 ...
CKD patients face higher CVD risk, with dyslipidemia differing from the general population, necessitating tailored lipid management strategies. Statin-based therapies, especially simvastatin plus ...
Older patients who have been discharged from the hospital after myocardial infarction are at a significantly lower risk of all-cause mortality if treated with high-intensity lipid-lowering therapy, ...
Another study explored goldenseal’s antioxidant activity as it applied to cholesterol. In an in vivo study with rats, all rats were given a high-cholesterol diet and then randomly assigned to either ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results